Plus Therapeutics, Inc. receives FDA Orphan Drug Designation for its Novel Glioblastoma Treatment Sep 1, 2020 Company Initiates Sixth Dosing Cohort in ReSPECT Trial Company Initiates Sixth Dosing Cohort in ReSPECT Trial
